chikungunya

Moderna “does not have plans” to advance its chikungunya antibody candidate to Phase 2, the company revealed last week in its third-quarter earnings press release. The Massachusetts-based mRNA specialist said it had completed a Phase 1 study of mRNA-1944 and would publish full results soon. Moderna also deprioritized a chikungunya vaccine candidate (mRNA-1388) in January 2020.

In other news, the New York Times reported Tuesday on an escalating dispute between Moderna and the U.S.…

Emergent BioSolutions has launched a U.S.-based Phase 3 trial of its CHIKV VLP single-dose chikungunya virus-like particle vaccine in healthy people ages 12-64, the Maryland-based company announced last week.

The announcement follows Phase 2 persistence data that showed people who received a dose of the adjuvanted candidate maintained neutralizing antibody titers for two years at levels 19 times higher than pre-vaccination.

Rivals including Bharat Biotech, Merck’s Themis…

Seoul’s International Vaccine Institute announced Tuesday that the first participant has been dosed with Bharat Biotech’s BBV87 two-dose, live-inactivated chikungunya vaccine in a Phase 2/3 trial in Costa Rica.

The trial is the first in a multicountry study—backed by the Coalition for Epidemic Preparedness Innovations (CEPI) and the Indian government’s Ind-CEPI initiative—to test the Hyderabad-based company’s shot in healthy adults in areas with endemic chikungunya, the press release…

Valneva reported positive Phase 3 results last week showing that its live attenuated, single-dose chikungunya shot produced neutralizing antibodies in 98.5% of subjects and was well-tolerated across age groups.

The company, which expects final results for VLA1553 within the next six months, is on course to be the first to win U.S. FDA approval and snag a Priority Review Voucher (PRV) for a chikungunya vaccine—ahead of rivals Emergent BioSolutions and Merck.

Meanwhile, Nature…

Valneva announced Wednesday that the U.S. FDA has granted its VLA1553 single-shot chikungunya vaccine candidate (currently in Phase 3) Breakthrough Therapy Designation—adding to the PRIority MEdicines (PRIME) designation the EMA awarded the French company’s jab in 2020 and the FDA Fast Track status it received in 2018.

Days after its CEO faced withering criticism from U.S. lawmakers over production mistakes with Covid-19 vaccines, Emergent BioSolutions had rosier news: two-year persistence data from a Phase 2 trial of the Maryland-based company’s chikungunya virus-like particle vaccine candidate (CHIKV-VLP) showed mean neutralizing antibody titers 19 times higher than pre-vaccination titers, according to a Wednesday press release.

Citing the lasting response to a single adjuvanted dose of the vaccine…

Vaccine makers Vaccitech and Valneva separately filed plans last week for initial public offerings on Nasdaq.

Oxford-based Vaccitech is the Jenner Institute spinout that owns the technology underlying the AstraZeneca/Oxford Covid-19 vaccine. Its pipeline includes a Phase 1 MERS vaccine and a preclinical zoster shot.

France’s Valneva, already listed on Euronext and proposing to list American depositary shares via a new offering, is seeking regulatory clearance to advance its…

France’s bioMérieux has secured European CE marking for three fully automated immunoassays for dengue, the company announced Wednesday.

Performed on the company’s Vidas family platforms, the Vidas Dengue NS1 Ag, Anti-Dengue IgM and Anti-Dengue IgG are “cost-effective and suitable for low- and middle-income countries,” according to the press release.

The company plans to add a chikungunya assay to its diagnostic offerings, per the announcement.

The Coalition for Epidemic Preparedness Innovations (CEPI) released a $3.5 billion investment case on Wednesday, outlining a five-year plan that includes a “moonshot” objective: compressing vaccine development timelines to 100 days.

Among the plan’s other goals are developing vaccines for known threats (such as chikungunya, Lassa fever and Nipah), producing a “library of prototype vaccines” from critical viral families, and supporting vaccine manufacturing in low- and middle-income…

Adjuvant Capital announced last week a $300 million Global Health Technology Fund focused on accelerating the development of medical innovations for “historically overlooked public health challenges.”

The New York-based social impact investor noted in its press release that it has already backed 14 companies, requiring each to make products broadly accessible to people in low- and middle-income countries. Adjuvant’s “young portfolio” includes investments in companies addressing…